ArticlePloS one2025
Trends in incidence and mortality of laryngeal cancer in china from 2004 to 2018: Projections to 2033 and decomposition analysis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long-term trends of laryngeal cancer incidence and mortality in China from 2004 to 2019 by region: age-period-cohort analysis and 15-years projections to 2034.Archives of public health = Archives belges de sante publique · 2026Article
- Deep learning radiomics nomogram predicts lymph node metastasis in laryngeal squamous cell carcinoma.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study analyzed trends in the incidence and mortality of laryngeal cancer (LC) in China from 2004 to 2018, provided projections up to 2033, and identified contributing factors influencing these trends. LC data were obtained from the Chinese Cancer Registry Annual Reports for 2004 to 2018. Estimated Annual Percent Change (EAPC) and 95% confidence intervals (CI) were calculated using Joinpoint Regression Software to evaluate trends. LC incidence and mortality rates in registry areas, combined with national population data, were used to estimate new cases and deaths. Projections were made to 2033, and a decomposition analysis identified factors influencing trends. From 2004 to 2018, the age-standardized incidence rate (ASIR) of LC decreased from 1.29 to 1.14 per 100,000, with an EAPC of -1.75% (95% CI: -2.36% to -1.12%). The age-standardized mortality rate (ASMR) also declined from 0.67 to 0.61 per 100,000, with an EAPC of -0.76% (95% CI: -1.28% to -0.25%). Mortality among males aged 60-69, however, showed a significant increase. Population growth and aging contributed to the rise in LC cases and deaths, while epidemiological factors partially offset these increases. By 2033, ASIR and ASMR for males and ASIR for females are projected to decrease, while ASMR for females is expected to rise. ASIR and ASMR in China showed a declining trend from 2004 to 2018, with further decreases projected through 2033. Yet, rising mortality in older males underscores the need for targeted prevention and early detection. Population aging and growth are key drivers of the LC burden, although epidemiological improvements have helped mitigate case increases. Comprehensive public health strategies remain essential to reduce LC impact in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.